November 2022

Infant Vaccine Coverage Declines to 13-Year Low

According to a recent publication in the CDC’s Morbidity and Mortality Weekly Report, in 2021 routine vaccination coverage among infants plunged to a 13-year low globally. Global estimates of coverage with three doses of diphtheria-tetanus-pertussis–containing vaccine decreased from an average of 86% during 2015-2019 to 83% in 2020 and 81% in 2021. Read more.



Pfizer Announces RSV Vaccine Candidate
Pfizer announced positive top-line data from the phase III clinical trial, MATISSE (MATernal Immunization Study for Safety and Efficacy), investigating its bivalent respiratory syncytial virus (RSV) prefusion vaccine candidate, RSVpreF or PF-06928316, when administered to pregnant participants to help protect their infants from RSV disease after birth. Learn more about the results of this study.

Study: Fluoxetine Safe for Pediatric Refractory Nocturnal Enuresis
Nocturnal enuresis is a major health problem affecting 15% of children aged older than 5 years. Even though an annual spontaneous resolution rate of 15% has been reported, 1% to 2% of teenagers aged older than 15 years and 2% to 6% of adults continue to deal with this issue. Learn more about a study exploring fluoxetine use in treating nocturnal enuresis in children.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App